CellTrend was the first to describe autoantibodies against GLP-1R and has filed a patent application. This patent covers a test system for the diagnosis, prognosis, and treatment monitoring of myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) in patients. The anti-GLP-1R antibody can only be determined by CellTrend using serum analysis.
